← Back to Search

Dengue Virus Challenge for Dengue Fever

Phase 1
Waitlist Available
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 6 months post virus inoculation
Awards & highlights

Summary

This trial uses a less harmful version of the dengue virus to see how volunteers react. The goal is to find out how safe it is and determine the best dose for future vaccine testing. Researchers will monitor participants closely for any symptoms or presence of the virus in their blood.

Who is the study for?
Healthy adults aged 18-50, who are not pregnant or breastfeeding and have no history of dengue or similar viral infections. Participants must understand the study and follow its requirements. Women able to bear children must use contraception before, during, and after the trial.
What is being tested?
The trial is testing different doses of an experimental weakened dengue virus to see if it causes symptoms or viremia when given intentionally (a 'challenge'). This helps determine safe dosages for future vaccine effectiveness trials.
What are the potential side effects?
Potential side effects may include typical symptoms associated with mild dengue fever such as headache, fever, muscle pain, joint pain, rash, nausea or vomiting. Since this is a challenge study with a live virus at controlled doses, close monitoring will be in place.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately six months
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately six months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of Abnormal Laboratory Measurements
Number of Participants with Dengue-Related Adverse Events
Number of Participants with Fever
+6 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Medium Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC)Experimental Treatment1 Intervention
0.95 x 10\^3 Plaque Forming Units
Group II: Low Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC)Experimental Treatment1 Intervention
0.95 x 10\^2 Plaque Forming Units
Group III: High Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC)Experimental Treatment1 Intervention
0.95 x 10\^4 Plaque Forming Units
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - High Dose
2022
Completed Phase 1
~30
Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose
2022
Completed Phase 1
~30
Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Medium Dose
2022
Completed Phase 1
~30

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Dengue Fever focus on supportive care, as there are no specific antiviral therapies approved for the disease. However, experimental approaches like the weakened dengue virus challenge aim to induce a controlled infection to study the immune response and ensure safety. This method helps researchers understand how the immune system reacts to the virus, which is crucial for developing effective vaccines. For Dengue Fever patients, this research is vital as it can lead to the creation of vaccines that provide immunity, reducing the incidence and severity of the disease.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor
706 Previous Clinical Trials
378,410 Total Patients Enrolled
Medical Technology Enterprise Consortium (MTEC)UNKNOWN
2 Previous Clinical Trials
48 Total Patients Enrolled

Media Library

Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose Clinical Trial Eligibility Overview. Trial Name: NCT05268302 — Phase 1
Dengue Fever Research Study Groups: Medium Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC), High Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC), Low Dose Dengue 4 Live Virus Human Challenge (DENV-4-LVHC)
Dengue Fever Clinical Trial 2023: Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose Highlights & Side Effects. Trial Name: NCT05268302 — Phase 1
Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose 2023 Treatment Timeline for Medical Study. Trial Name: NCT05268302 — Phase 1
~8 spots leftby Oct 2025